Life Biosciences Will Present ER-100 Trial Data in October
The company will report interim phase 1 safety and tolerability results for its epigenetic therapy on October 8, 2026.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you support prioritizing research that attempts to reverse diseases associated with aging?
Life Biosciences is scheduled to present interim phase 1 clinical trial data for its optic neuropathy treatment, ER-100, on October 8, 2026. The research-stage trial, which began in the first quarter of 2026, assesses the safety of the therapy in patients with conditions including open-angle glaucoma.
Why it matters
The study addresses a significant clinical gap, as current optic neuropathies lack therapeutic options that restore damage to retinal ganglion cells. This trial represents a test of whether epigenetic reprogramming can safely influence cellular function in humans.
The ER-100 platform utilizes a trio of transcription factors—OCT4, SOX2, and KLF4—to induce youthful gene expression patterns. This mechanism aims to reset the epigenetic code of cells, a process that is currently in clinical-stage evaluation for its safety and tolerability.
The players
Life Biosciences
A Boston-based biotechnology company developing epigenetic therapies that use transcription factor modulation to address age-related cellular decline.
The details
The treatment functions by modulating gene expression to rejuvenate damaged cells, specifically targeting retinal ganglion cells—neurons that transmit visual information from the eye to the brain. By using controlled expression of specific transcription factors, the platform attempts to reverse the biological aging of these cells. This trial is evaluating the approach in patients diagnosed with non-arteritic anterior ischemic optic neuropathy and open-angle glaucoma.
Timeline
The phase 1 clinical trial was initiated in the first quarter of 2026.
Interim trial data will be presented on October 8, 2026.
The Tech Race
This trial marks a progression in the application of Yamanaka factor-based cellular reprogramming, moving from laboratory models to human safety assessments. The company is currently competing to prove that these potent gene-regulatory factors can be controlled safely within the human eye.
This development is currently limited to a phase 1 clinical trial and is not available for clinical use or public prescription. Patients and providers should watch for the October 8 safety results, which will determine if the therapy moves to subsequent phases of human testing.
The takeaway
The field is moving toward human trials for epigenetic cellular reprogramming, testing if we can modify cellular age to treat blindness. Readers should track the safety data reported at Eyecelerator to see if this platform successfully clears the first human benchmark.
What happens next
Life Biosciences will present interim data at the Eyecelerator meeting in New Orleans, LA, on October 8, 2026.
Further reading
For more on the latest research in the field, visit Biotech.
More information
View the clinical trial study details at the official government database.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you support prioritizing research that attempts to reverse diseases associated with aging?
